AI cuts biopharma drug development costs and risks, boosting asset values dramatically.

AI technology is transforming the biopharma industry by significantly reducing the time, cost, and risk associated with drug development. This shift recalibrates how companies are valued, with AI-enabled assets showing a substantial increase in risk-adjusted net present value—from a modeled negative $238.5 million to a positive $356.5 million. Major companies like Eli Lilly are investing in proprietary AI systems and partnerships, creating competitive advantages and new revenue streams. While smaller biotechs can also benefit from advanced AI platforms, challenges remain, including regulatory, model, and data risks that could impact outcomes.